BIOCORP overview

Regulatory News: Following the announcement of the planned acquisition of BIOCORP Production SA (FR0012788065 - ALCOR) (“ BIOCORP ”) by NOVO NORDISK (DK0060534915 - Novo-B), a leading global healthcare company headquartered in Denmark and developing treatments against diabetes and other chronic diseases (“ NOVO NORDISK ”), released on June 5, 2023, BIOCORP announces that, following receipt of customary regulatory approvals, NOVO NORDISK has today completed the off-market acquisition from...

Regulatory News: Following the announcement, on June 5 th , 2023 of the contemplated acquisition of BIOCORP Production SA (FR0012788065 – ALCOR) (Paris:ALCOR) (“BIOCORP“), a French company specialized in the design, development and manufacturing of delivery systems and innovative medical devices, by NOVO NORDISK (DK0060534915 – Novo-B), a leading global healthcare company headquartered in Denmark whose purpose is to drive change to defeat diabetes and other serious chronic diseases...

Regulatory News: Novo Nordisk A/S and BIOCORP Production SA (Paris:ALCOR) announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP 1 at a price of 35.00 Euros per share in cash, representing a total equity value of approximately 154 million Euros. BIOCORP is a French company specialized in the design, development and manufacturing of...

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, today announces its annual results for the year ended on December 31, 2022, as approved by the Board of directors on March 27 th . Eric Dessertenne, CEO of BIOCORP, commented: "More products, more partnerships and more geographical areas to cover. In a macro-economic environment that remains as complex as...

Regulatory News: This replaces the announcement made at 6 PM CET on January 5th 2023 due to the following corrections: The release date for the 2022 annual results has been brought forward to March 29, 2023. BIOCORP: 2023 financial calendar BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its financial reporting schedule for 2023 (1) . Annonce Date* 2022...

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today the signature of a contract with HRA Pharma (an affiliate of the global consumer self-care leader Perrigo Company plc). This agreement concerns the development and industrialization of an innovative medical device aiming to provide instant relief and faster healing of skin injuries. After an...

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its financial reporting schedule for 2023 (1) . Annonce Date* 2022 full-year results Thursday, April 6 th , 2023 Before the market opening Annual shareholders meeting Tuesday, May 16 th , 2023 2023 first-half results Thursday, September 28 th , 2023 Before the market opening (1) This schedule is...

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received the EU production quality assurance certificate according to the new regulation for non-sterile medical devices with measurement function for drug administration. This new European regulation 2017/745, which came into force on May 26, 2021, offers an important...